Jarrod Ross Mcgahan, MD
Family Practice · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Sutter Bay Medical Foundation · Sutter Valley Medical Foundation
Looking this up.
Hospitals listed: Sutter Roseville Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Mcgahan’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A140903 · Current
Licensed to practise in California · since 2016 · expires 2028-02-29 · University of Louisville School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Sutter Roseville Medical CenterRoseville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.56) · 12,400 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.069, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.262, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.128, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.357, Oct 2024 – Sep 2025
See every measure and the patient survey for Sutter Roseville Medical Center
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 5 better, 1 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.56) · 12,400 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.069 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.128 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.357 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.33 (0.49 to 2.17) · 2,916 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 147.2 (107.33 to 187.07) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.7 · 484 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 839 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 1,027 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 656 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 6,822 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.08 to 0.42) · 14,300 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.06 to 0.41) · 14,490 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.43 (2.77 to 6.08) · 3,117 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0 to 2.95) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.06 (0.76 to 3.36) · 2,944 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (2.8 to 15.25) · 840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.43 (3.11 to 9.75) · 899 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.34 to 3.11) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 0.41 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 527 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 1,094 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -16.6 · 443 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 961 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 1,064 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 1,293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.7) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (6.9 to 14.9) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.5 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.9) · 116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 1,600 cases | No different | Jan 2024 – Dec 2024 |
What patients said (537 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$26,346
Medicare paid this office $26,346 for 226 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 175 | $17,059 | $92 |
| Long return visit (40+ min) | 32 | $4,621 | $144 |
| Injection of drug or substance under skin or into muscle | 12 | $158 | $12 |
| Automated urinalysis test | 41 | $92 | $2 |
Procedures Medicare counted
| Removal of tissue | 1-10 | None |
Who their Medicare patients are
226 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 17% · Women 70% · Also on Medicaid 11% · Health risk score 1.18. Above the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 72% · Coronary heart disease 27% · Diabetes 25% · Chronic kidney disease 25% · Atrial fibrillation 23% · COPD 22% · Depression 20% · Cancer 19% · Heart failure 15% · Dementia 6% · Stroke 5%.
The office billed $103,178, Medicare allowed $36,514 and paid $26,346; for 404 services of 41 kinds; $50 of it was for drugs given in the office and $26,295 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 226 | 404 | 75 | 1.18 | $103,178 | $26,346 |
| 2023 | 257 | 425 | 74 | 1.02 | $104,681 | $30,676 |
| 2022 | 321 | 496 | 74 | 1.09 | $124,154 | $39,534 |
| 2021 | 233 | 404 | 74 | 1.05 | $96,053 | $28,778 |
| 2020 | 268 | 433 | 74 | 1.30 | $95,818 | $23,739 |
| 2019 | 337 | 513 | 74 | 1.26 | $130,767 | $30,917 |
| 2018 | 328 | 610 | 74 | 1.30 | $122,845 | $30,076 |
| 2017 | 81 | 139 | 72 | 1.11 | $27,543 | $7,991 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 196 | $20,346 | $98 |
| Long return visit (40+ min) | 43 | $6,541 | $152 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 20 | $1,006 | $50 |
| Automated urinalysis test | 28 | $62 | $2 |
2022: 6 services
| Return visit (30+ min) | 265 | $28,363 | $105 |
| Long return visit (40+ min) | 43 | $6,275 | $146 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 49 | $2,480 | $51 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 11 | $179 | $16 |
| Detection test by immunoassay with direct visual observation for influenza virus | 11 | $179 | $16 |
| Automated urinalysis test | 28 | $62 | $2 |
2021: 5 services
| Return visit (30+ min) | 184 | $18,674 | $98 |
| Long return visit (40+ min) | 33 | $4,625 | $136 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 32 | $1,745 | $51 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 11 | $182 | $17 |
| Automated urinalysis test | 31 | $70 | $2 |
2020: 5 services
| Return visit (30+ min) | 165 | $14,521 | $82 |
| Long return visit (40+ min) | 40 | $4,326 | $108 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 36 | $717 | $20 |
| Injection of drug or substance under skin or into muscle | 13 | $176 | $10 |
| Automated urinalysis test | 34 | $83 | $2 |
2019: 5 services
| Return visit (30+ min) | 248 | $19,438 | $76 |
| Long return visit (40+ min) | 65 | $6,689 | $103 |
| Injection of drug or substance under skin or into muscle | 18 | $212 | $12 |
| Automated urinalysis test | 29 | $71 | $2 |
| Injection, ketorolac tromethamine, per 15 mg | 16 | $14 | None |
2018: 5 services
| Return visit (30+ min) | 231 | $17,500 | $74 |
| Long return visit (40+ min) | 65 | $7,387 | $114 |
| Injection of drug or substance under skin or into muscle | 41 | $675 | $16 |
| Automated urinalysis test | 31 | $87 | $3 |
| Injection, ketorolac tromethamine, per 15 mg | 31 | $43 | None |
2017: 2 services
| Return visit (30+ min) | 59 | $5,246 | $87 |
| Long return visit (40+ min) | 12 | $1,424 | $119 |
Medicaid work
$2,430 in 2024
Medicaid paid $2,430 for 48 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 48 | $2,430 |
| 2024 | 48 | 1 | 17 | $2,430 |
| 2023 | 37 | 1 | 12 | $1,823 |
| 2022 | 80 | 1 | 20 | $4,248 |
| 2021 | 12 | 1 | 12 | $768 |
| 2020 | 14 | 1 | 14 | $838 |
| 2019 | 39 | 1 | 25 | $2,097 |
| 2018 | 82 | 1 | 19 | $4,919 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 37 | $1,823 |
2022
| Return visit (30+ min) | 80 | $4,248 |
2021
| Return visit (30+ min) | 12 | $768 |
2020
| Return visit (30+ min) | 14 | $838 |
2019
| Return visit (30+ min) | 39 | $2,097 |
2018
| Return visit (30+ min) | 82 | $4,919 |
Drugs they prescribed that Part D paid
$7,619
Pharmacies billed $7,619 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
261 generic and fewer than 11 brand-name prescriptions · $7,619 in drug cost · 139 antibiotic prescriptions to 126 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Valacyclovir | 11 | $370 | $34 |
| Cephalexin | 26 | $267 | $10 |
| Nitrofurantoin Mono-Macro | 23 | $250 | $11 |
| Amoxicillin-Clavulanate Potass | 23 | $181 | $8 |
| Mupirocin | 12 | $117 | $10 |
See all 10 drugs
| Valacyclovir | 11 | $370 | $34 |
| Cephalexin | 26 | $267 | $10 |
| Nitrofurantoin Mono-Macro | 23 | $250 | $11 |
| Amoxicillin-Clavulanate Potass | 23 | $181 | $8 |
| Mupirocin | 12 | $117 | $10 |
| Polymyxin B Sul-Trimethoprim | 15 | $113 | $8 |
| Azithromycin | 23 | $71 | $3 |
| Sulfamethoxazole-Trimethoprim | 18 | $68 | $4 |
| Prednisone | 17 | $38 | $2 |
| Paxlovid | 11 | $0 | $0 |
Year by year
| 2024 | 308 | 223 | None | None | $7,619 |
| 2023 | 318 | 235 | None | 8% | $6,004 |
| 2022 | 384 | 273 | None | 5% | $5,612 |
| 2021 | 226 | 157 | None | 6% | $4,180 |
| 2020 | 207 | 146 | None | 12% | $4,226 |
| 2019 | 338 | 241 | 3% (11) | 8% | $10,173 |
| 2018 | 295 | 200 | 5% (15) | 9% | $8,889 |
| 2017 | 545 | 111 | 6% (33) | 20% | $35,023 |
| 2016 | 316 | 57 | 12% (37) | None | $15,703 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Albuterol Sulfate Hfa | 16 | $434 | $27 |
| Ofloxacin | 11 | $434 | $39 |
| Nitrofurantoin Mono-Macro | 19 | $316 | $17 |
| Amoxicillin-Clavulanate Potass | 28 | $291 | $10 |
| Paxlovid (Eua) | 25 | $246 | $10 |
| Azithromycin | 41 | $220 | $5 |
| Cephalexin | 20 | $166 | $8 |
| Benzonatate | 12 | $153 | $13 |
| Sulfamethoxazole-Trimethoprim | 14 | $105 | $8 |
| Prednisone | 31 | $96 | $3 |
2022: 11 drugs
| Ofloxacin | 12 | $579 | $48 |
| Albuterol Sulfate Hfa | 15 | $505 | $34 |
| Azithromycin | 54 | $422 | $8 |
| Paxlovid (Eua) | 38 | $385 | $10 |
| Fluticasone Propionate | 22 | $285 | $13 |
| Benzonatate | 16 | $219 | $14 |
| Cephalexin | 27 | $193 | $7 |
| Prednisone | 44 | $190 | $4 |
| Amoxicillin-Clavulanate Potass | 12 | $133 | $11 |
| Amoxicillin | 17 | $85 | $5 |
| Sulfamethoxazole-Trimethoprim | 13 | $62 | $5 |
2021: 5 drugs
| Cefdinir | 11 | $233 | $21 |
| Azithromycin | 32 | $162 | $5 |
| Cephalexin | 26 | $132 | $5 |
| Prednisone | 20 | $65 | $3 |
| Sulfamethoxazole-Trimethoprim | 15 | $64 | $4 |
2020: 4 drugs
| Cephalexin | 30 | $205 | $7 |
| Azithromycin | 24 | $171 | $7 |
| Prednisone | 16 | $74 | $5 |
| Sulfamethoxazole-Trimethoprim | 11 | $47 | $4 |
2019: 7 drugs
| Fluticasone Propionate | 27 | $609 | $23 |
| Ofloxacin | 11 | $497 | $45 |
| Cephalexin | 39 | $333 | $9 |
| Cefdinir | 13 | $296 | $23 |
| Azithromycin | 43 | $272 | $6 |
| Prednisone | 29 | $96 | $3 |
| Sulfamethoxazole-Trimethoprim | 15 | $89 | $6 |
2018: 8 drugs
| Fluticasone Propionate | 41 | $810 | $20 |
| Ofloxacin | 13 | $331 | $25 |
| Cephalexin | 35 | $327 | $9 |
| Nitrofurantoin Mono-Macro | 13 | $327 | $25 |
| Azithromycin | 28 | $137 | $5 |
| Ciprofloxacin | 11 | $82 | $7 |
| Sulfamethoxazole-Trimethoprim | 14 | $57 | $4 |
| Hydrocodone-Acetaminophen | 11 | $39 | $4 |
2017: 16 drugs
| Ultra-Fine Mini Pen Needle | 14 | $537 | $38 |
| Levothyroxine | 19 | $439 | $23 |
| Oxybutynin Chloride Er | 13 | $346 | $27 |
| Hydrocodone-Acetaminophen | 16 | $326 | $20 |
| Gabapentin | 14 | $279 | $20 |
| Potassium Chloride | 12 | $253 | $21 |
| Atorvastatin | 21 | $251 | $12 |
| Lisinopril | 29 | $228 | $8 |
| Fluticasone Propionate | 11 | $173 | $16 |
| Omeprazole | 12 | $169 | $14 |
| Furosemide | 11 | $159 | $14 |
| Carvedilol | 20 | $136 | $7 |
| Azithromycin | 12 | $86 | $7 |
| Hydrochlorothiazide | 12 | $68 | $6 |
| Simvastatin | 18 | $60 | $3 |
| Escitalopram | 12 | $45 | $4 |
2016: 7 drugs
| Hydrocodone-Acetaminophen | 19 | $464 | $24 |
| Levothyroxine | 16 | $419 | $26 |
| Morphine Sulfate Er | 11 | $388 | $35 |
| Lisinopril | 24 | $124 | $5 |
| Gabapentin | 13 | $108 | $8 |
| Fluticasone Propionate | 17 | $82 | $5 |
| Simvastatin | 11 | $72 | $7 |
Professional record
- NPI
- 1770994055
- Licence
- CA A140903California A140903: Current · expires 2028-02-29
- Group
- Sutter Bay Medical Foundation · Sutter Valley Medical Foundation
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X); Student in a training program (390200000X)
- Mailing address
- 10470 Old Placerville Rd Ste 100, Sacramento, CA, 95827
- NPI first listed
- 2014-05-08
- NPI last updated
- 2022-07-21
This is when the NPI record was last certified, not a medical board exam.